Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

View:
Post by postie1 on Jan 28, 2023 10:52am

Good to see

According to the news release former directors chose to take money owed in shares rather than cash. Must think there is much better value in the shares long term than cash . DYDD
Comment by sylvain_007 on Jan 29, 2023 10:56am
I hope shareholders will post most frequently tha they did at this moment. We need more informations on this site.
Comment by postie1 on Jan 30, 2023 9:04am
I think the reason there are not more posts on this thread is because those of us that have been in VM for several years have read the game plan on VM webpage and are just watching them follow the steps(not always as fast as we would wish for).  (IMO) the real sustained upward movement in the share price will be when production and sales are in full swing. Until then I personnally think when ...more  
Comment by Cavest on Jan 30, 2023 9:43am
I agree with you Postie1. VM will probably double in value over the next 2 years, maybe in 2 weeks, 8 months or 18 months… patience! I haven’t had a chance to exercise my warrants for my first 2 PP (0.05 and 0.15), but I would love to exercise my options for the last PP (0.07)… I'm not adding shares but will wait to sell on the ask over 0.2$.
Comment by Sweeper on Jan 30, 2023 11:05am
Alot of positives for this little play. Very bold plan for a lucrative niche market. Anyone have any opinions (more or less) on the 50+ million financing?   
Comment by postie1 on Jan 30, 2023 1:47pm
Should know before end of February and these guys have been very tight lipped to date on everything. Just my opinion and do not trade on that but I think the sudden interest in volume and the fact they are negotiating financing is not a coincidence. Do not forget that the PEA was done when Barite prices were much lower so that cash flow could be much higher.  I am watching for:  2000 ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1